<DOC>
	<DOC>NCT00560053</DOC>
	<brief_summary>The study objectives are to investigate the toxicity and the BUMEL response rate; in patients who reach the CR after autotransplantation, investigate if negativization of IF, influences in disease evolution; in patients in PR after autotransplantation, analyze if the second intensive procedure is capable of increasing the response rate and increasing the survival so that patients who reached the CR with the first transplantation; Patients with MM primarily resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients submitted to double transplantation, control the efficacy of the second transplantation in front of allogenic transplantation.</brief_summary>
	<brief_title>Pethema Multiple Myeloma 2000</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Less 70 years ECOG 02 Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia, extramedulary plasmocytoma, creatinine &gt;2 mg/dl). No previous chemotherapy &gt;70 years ECOG 34 myeloma quiescent cardiopathy liver disfunction HIV+ Hepatitis BC + Previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Alternating chemotherapy</keyword>
	<keyword>Transplantation</keyword>
</DOC>